Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > 11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.

Title11C-CFT-PET in Presymptomatic FTDP-17: A Potential Biomarker Predicting Onset.
Publication TypeJournal Article
Year of Publication2018
AuthorsWu, L, Liu, J, Feng, X, Dong, J, Qin, W, Liu, Y, Wang, J, Lu, J, Chen, K, Wang, Y, Jia, J
JournalJ Alzheimers Dis
Volume61
Issue2
Pagination613-618
Date Published2018
ISSN1875-8908
KeywordsAdult, Biomarkers, Brain, Carbon Radioisotopes, Female, Frontotemporal Dementia, Heterozygote, Humans, Male, Middle Aged, Mutation, Parkinsonian Disorders, Pedigree, Positron-Emission Tomography, tau Proteins
Abstract

Frontotemporal dementia with parkinsonism-linked to chromosome 17 (FTDP-17) is a rare autosomal dominant neurodegenerative disorder. Most patients with FTDP-17 carry the mutation in the microtubule-associated protein tau (MAPT) gene. Striatum is predominantly and early affected in FTDP-17. Five family members (two symptomatic patients and three presymptomatic mutation carriers) from a Chinese pedigree of FTDP-17 with N279K mutation in MAPT were enrolled. Parkinsonism was the initial symptom for symptomatic patients. 2b-carbomethoxy-3b-(4-trimethylstannylphenyl) tropane (11C-CFT) uptake was obviously affected in the putamen of two presymptomatic mutation carriers. Presymptomatic case 3, whose 11C-CFT uptake in the right putamen was normal at baseline, was still free of parkinsonism during follow-up. In conclusion, 11C-CFT-positron emission tomography could be a potential biomarker for the presymptomatic stage of FTDP-17 to predict the disease onset.

DOI10.3233/JAD-170561
Alternate JournalJ. Alzheimers Dis.
PubMed ID29226866
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/11c-cft-pet-presymptomatic-ftdp-17-potential-biomarker-predicting-onset